原发性肝癌介入治疗对尿激酶型纤溶酶原激活剂及其受体表达的影响

  目的 探索原发性肝癌介入治疗前后尿激酶型纤溶酶原激活剂（urokinase plasminogen activator, uPA）及其受体（urokinase plasminogen activator receptor, uPAR）表达的变化，分析uPA及uPAR在人类原发性肝癌发生发展中的作用，并为uPA及uPAR表达水平对介入治疗原发性肝癌的效果评价价值提供可靠的理论依据。方法 对48例已确诊的原发性肝癌患者在介入治疗前后分别取静脉血、癌组织和肝正常区组织标本，应用ELISA、RT-PCR方法，分别检测介入治疗前后uPA／uPAR在血清、肝癌组织与正常肝组织中的表达变化。结果 介入治疗前uPA／uPAR 在血清内的表达量明显高于对照组，两组间的差异有统计学意义（P＜0.01）；肝癌组织中uPA／uPAR mRNA明显高于正常区肝组织，两组间的差异有统计学意义（P＜0.01），且介入治疗后肝癌组织中uPA／uPAR mRNA的表达量较治疗前明显降低，两组间的差异有统计学意义（P＜0.05），但未降至正常。结论 uPA／uPAR 的过量表达与原发性肝癌的发生有关，uPA／uPAR的mRNA表达水平对介入治疗原发性肝癌的效果评价有一定的参考价值。

The effects on the expression of uPA/uPAR before and after the interventional therapy of primary hepatocellular carcinoma

Objective To study the effects on the expression of uPA / uPAR before and after the interventional therapy of primary hepatocellular carcinoma and analyse the function of the expression of uPA / uPAR on the carcinogenesis and development of primary hepatocellular carcinoma., so as to provide a standard to evaluate the effects on the interventional therapy of primary hepatocellular carcinoma. Methods To analyze the uPA / uPAR in sera of control and patients with ELISA. The mRNA expression levels of uPA / uPAR were assessed by RT-PCR method in the hepatocellular carcinoma tissues and tumor free tissues from 48 patients with primary hepatocellular carcinoma before and after the interventional therapy. Tissue specimens were obtained by biopsy, and confirmed by histological evaluation. Results The uPA / uPAR in patients sera before interventional therapy were higher than those in control group (P <0.01). The mRNA levels of uPA / uPAR were increased in hepatocellular carcinoma tissues compared with normal tissues from tumor free tissues (P <0.01) and significantly decreased after the interventional therapy(P >0.05). Conclusions The overexpression of uPA / uPAR are of great significance in the carcinogenesis and development of gastric carcinoma, might be used as a standard to evaluate the effects on the interventional therapy of primary hepatocellular carcinoma.